COMP <GO>
PBH vs MRK // ENTERPRISE SCALE & MARKET CAP
Prestige Consumer Healthcare Inc. (NYSE) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: PBH 4
— MRK 9
▲ ENTERPRISE SCALE & MARKET CAP LEADER: MRK
LAST: $49.06 (+0.64%) • MKT CAP: $2.31B
market-cap
$2.31B
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
market-cap
$361.02B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PBH VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PBH | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.70% | 74.80% | -20.10 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.80% | 20.70% | -6.90 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.0x | 15.3x | -8.30 | PBH | /valuation <GO> |
| Free Cash Flow Yield | 10.67% | 3.42% | +7.25 | PBH | /fcf-yield <GO> |
| Operating Margin | 28.40% | 34.30% | -5.90 | MRK | /operating-margins <GO> |
| Net Profit Margin | 17.50% | 28.10% | -10.60 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -4.30% | 1.30% | -5.60 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.21 | 5.19 | -2.98 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.5 | 51.7 | +0.80 | PBH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.3x | 18.4x | -7.10 | PBH | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $2.31B | $361.02B | -$358.71B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PBH REV | MRK REV | PBH GROSS % | MRK GROSS % | PBH FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.09B | $65.01B | 54.7% | 74.8% | $246.4M | $12.36B |
| FY 2024 | $1.14B | $64.17B | 55.8% | 76.3% | $243.3M | $18.10B |
| FY 2023 | $1.13B | $60.12B | — | — | $248.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PBH // BETA —
MRK // BETA 0.92